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 Abstract    
Effects of interleukin (IL) on intracellular free Ca2+ concentration ([Ca2+]i) rise and 
catecholamine (CA) release were examined in isolated, cultured bovine adrenal chromaffin 
cells. IL-1α and IL-1β inhibited the rise of [Ca2+]i and CA release induced by acetylcholine 
(ACh) and excess KCl both in normal and in Ca2+-sucrose medium. IL-1 receptor 
antagonist, IL-1RA by pretreatment blocked the inhibitory actions of IL-1. IL-1α reduced 
CA release induced by veratridine in normal medium but not in the presence of diltiazem. 
Analysis using specific blockers for voltage-operated Ca2+ channels revealed that IL-1α 
specifically inhibited the P/Q-type Ca2+ channel to reduce [Ca2+]i rise induced by excess 
KCl. IL-1 did not affect [Ca2+]i rise induced either by bradykinin or caffeine in Ca2+-
deprivated medium or via activation of store-operated Ca2+ channel. The inhibitory effects 
of IL-1 were blocked by pretreatments of cells with herbimycin A, U0126 and PD 98054, 
but not with SB202190, SP 600125 or pertussis toxin (PTX), inhibited the induction of the 
inhibitory action of IL-1.  
     These results demonstrated that IL-1 inhibits stimulation-evoked [Ca2+]i rise and CA 
release in chromaffin cells by blocking voltage-operated P/O-type Ca2+ channels. The 
inhibitory action of IL-1 may be mediated through tyrosine kinase and MEK/ERK 
pathways.
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Introduction 
     
 The most prominent neuroendocrine system for host defense against diseases and stress 
is activation of the hypothalamic-pituitary-adrenal gland (HPA) axis, resulting in the 
release of adrenocorticotropic hormone and glucocorticoids. Cytokines are the most potent 
regulators of the HPA axis [1, 2]. In addition to this axis, catecholamine (CA) release from 
adrenal medulla also forms an important mechanism for host defense against diseases and 
stress. The secretory response of CA in adrenal medullary chromaffin cells comes under 
central control via the splanchnic nerve. It receives peripheral regulation (such as auto-
regulation) by various factors which are co-released with CA from chromaffin cells, and 
circular regulation by factors in the blood which increase or decrease in response to 
diseases and stress [3]. Cytokines are induced in circulation under some conditions, 
including severe trauma and fever [4-9]. Interleukin (IL)-1α has been localized 
immunohistochemically to peripheral neurons with a distribution pattern similar to that of 
noradrenergic fibers [10, 11] and in rat adrenal medulla where its expression is altered by 
physiological stimulation of adrenomedullary chromaffin cells [12]. Induction of IL-1 like 
substances in PC 12 cells by NGF [13] and induction of IL-1α mRNA by various 
stimulations in bovine adrenal chromaffin cells [14] and in PC 12 cells [15], and the release 
of IL-1 form bovine adrenal chromaffin cells [16] have been reported. These results suggest 
that cytokines may play a physiological role in adrenal medullary functions. In support of 
this idea, cytokines have been shown to differentially regulate neuropeptide biosynthesis in 
bovine adrenal chromaffin cells [17]. Furthermore, Yanagihara et al. [18] reported that 
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long-time exposure of bovine adrenal chromaffin cells with IL-1β increased CA release 
from the cells. Therefore, it is assumed that cytokines directly regulate the process leading 
to the exocytotic release of CA from adrenomedullary chromaffin cells. To address this 
issue, we examined the effect of cytokines on intracellular Ca2+ dynamics and CA release 
in adrenal medullary chromaffin cells. It was found that IL-1 produced a significant 
inhibitory effect on stimulation-induced increase in intracellular free Ca2+ concentration 
([Ca2+]i) and release of CA by selectively inhibiting voltage-dependent P/Q-type Ca2+ 
channels. 
  
1. Materials and methods 
 
2.1. Materials 
 
The drugs used were recombinant human IL-1α, human IL-1β, human IL-1RA, (R&D 
systems Inc., Minneapolis, MN, USA); bradykinin, ω-agatoxin IVA, ω-conotoxin GVIA 
and ω-conotoxin MVIIC (Peptide Institute Inc., Osaka, Japan); caffeine, digitonin, 
herbimycin A and pertussis toxin (Wako Pure Chemicals Industries, Osaka, Japan); 
diltiazem hydrochloride, nicardipine hydrochloride, nifedipine, thapsigargin and veratridine 
(Sigma, St. Louis, MO, USA); PD 98059 [2’-amino-3’-methoxyflavone], SB 202190 [4-(4-
fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole], SP600125 [Anthra[1,9-
cd]pyrazol-6(2H)-one; JNK inhibitor II] and U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-
aminophenylthio)butadiene] (Calbiochem, LaJolla, CA, USA) and fura-2 acetoxymethyl 
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ester (fura-2/AM) (Dojindo Chemicals, Kumamoto, Japan). All other chemicals were 
reagent grade and purchased from commercial sources specified elsewhere. Nicardipine 
and veratridine were dissolved in ethanol. Diltiazem, fura-2/AM, herbimycin A, nifedipine, 
PD 98059, SB 202190, SP600125 and U0126 were dissolved in dimethyl sulfoxide and 
diluted appropriately (final concentration of ethanol and dimetyl sulfoxide was 0.1%). 
 
2.2. Cell preparation and culture 
 
Chromaffin cells of bovine adrenal glands were isolated enzymatically according to the 
procedure described by [19], with some modifications [20, 21]. Cells were maintained in 
Dulbecco’s modified Eagle’s medium containing 10 % fetal calf serum, penicillin G 100 
units/ml, streptomycin 100 µg/ml, ascorbate 0.1 mM, and HEPES 5 mM for 24 - 72 h at 
37 °C under 5 % CO2/95 % air as suspension culture for measurements of [Ca2+]i, or as 
monolayer culture on  35 mm tissue culture Petri dish (5x105 cells/ml) for 2 - 5 days for CA 
release assay. Cells were washed and suspended before use in a medium containing NaCl 
150; KCl 5; MgSO4 1; CaCl2 1.3; glucose 5; HEPES-Tris buffer 10 (in mM) and bovine 
serum albumin (BSA) 0.5 %, pH 7.4 or Ca2+-sucrose medium containing CaCl2 1.3 mM, 
sucrose 340 mM HEPES-Tris 10 mM and BSA 0.1 %, pH 7.35. 
 
2.3. Measurements of [Ca2+]i 
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For the measurement of [Ca2+]i, cells were incubated at 32 °C with 1 µM fura-2 AM for 
30 min in order to load the dye. Cells were then centrifuged at 15 g for 10 min and 
resuspended to yield 3 x 106 cells/ml. Fluorescence was measured using a dual wavelength, 
fluorescence spectrophotometric mode, with an excitation of 340 and 380 nm, and an 
emission of 510 nm as described previously [22]. [Ca2+]i was calculated from the 
fluorescent ratio at 340 and 380 nm, using the equation of Grynkiewikcz et al. [23] and a 
value of 224 nM for the Kd of fura-2.  
 
2.4. Measurement of catecholamine (CA) release 
 
To measure CA release from permeabilized chromaffin cells, cells in monolayer culture 
were permeabilized with 10 µM of digitonin in a Ca2+-free KGP-solution (150 mM 
gultamate potassium salt, 10 mM PIPES, 5 mM nitrilotriacetic acid, 4.5 mM magnesium 
acetate, pH 7.0) containing 5 mM Mg-ATP, 0.5 mM EGTA and 0.1 % BSA as described 
previously [22]. Cells were then incubated for 20 min with KGP-solution containing 
various amounts of calcium chloride to yield the indicated free Ca2+ concentrations. After 
the incubation, the medium was immediately separated from the cells, then perchloric acid 
was added (5 % of final concentration) and the mixture was centrifuged at 4,500 g for 15 
min. IL-1s were added 40 min before the permeabilization with digitonin.  
CA release from intact cultured bovine chromaffin cells was performed as previously 
described [20, 21]. Cultured bovine adrenal chromaffin cells were incubated for 30 min 
with or without 100 pg/ml IL-1α. The medium was replaced with fresh medium containing 
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IL-1α and ACh, excess KCl at the concentrations indicated, then further incubated for 9 
min at 37 °C. The total CA content of the clear supernatant was measured fluorometrically 
by the method of von Eular and Lishajko [24] with adrenaline as a standard. Values were 
represented as net increase in CA release (stimulated release – corresponding basal 
release). 
The determination of the ratio of NE/(NE + E) in the medium was performed using 
HPLC-ED as previously described Sakuma et al. [25].  
 
2.5. Statistics 
 
All experiments were carried out in triplicate, and each experiment was repeated at least 
3 times. Data obtained are expressed as mean ± SEM. Statistical significance between 
means for comparison of two variables was estimated using the Student’s t-test. P<0.05 
was considered statistically significant. 
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Results 
 
Inhibition by IL-1 of stimulation-evoked CA release 
 
Pretreatment of cultured bovine adrenal chromaffin cells with 100 pg of IL-1α had little 
affect on basal CA release (Basal CA release during 30 min incubations were 0.15 ± 0.01 
[control] and 0.16 ± 0.01 μg/106 cells [100 pg IL-1α], respectively, n=25) and significantly 
inhibited stimulation-induced CA release (Table 1). IL-1α reduced even the maximal 
release induced by 30 μM ACh and 75 mM KCl. In Ca2+ sucrose medium, 25 mM KCl 
induced larger CA release than in normal medium. IL-1α reduced CA release in this 
condition to an extent similar to the normal medium. Veratridine, a Na+-ionophore, caused 
CA release by activating Na+-Ca2+ exchange through the plasma membrane and voltage-
operated Ca2+ channel (VOCC), a result of the cytosolic accumulation of Na+ in chromaffin 
cells [26, 27]. IL-1α reduced veratridine-induced CA release but this effect was lost in the 
presence of diltiazem, an inhibitor of VOCC. IL-1α had no effect on Ca2+-induced CA 
release from digitonin-permeabilized cells. IL-1 receptor antagonist, IL-1RA blocked the 
inhibitory effect of IL-1α by pretreatment of cells with IL-1RA. However, when cells were 
treated with IL-IRA at 30 min after the treatment of IL-1α then incubated for 90 min, the 
inhibitory effect of IL-1α on ACh-induced CA release was not recovered. Basal release in 
intact cells with the normal and Ca2+-Sucrose solutions and permeabilized cells (at 10 nM 
free Ca2+ concentration) were 0.08 ± 0.01, 0.55 ± 0.02 and 0.17 ± 0.02 μg/106 cells, 
respectively. Basal CA release was not altered by the presence of the drugs tested and/or 
IL-1α. The effects of IL-1α on CA content and the ratio of released norepinephrine (NE) 
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and epinephrine (E) were examined. Total CA in cells treated with or without IL-1α, 100 
pg/ml for 0, 30, 60 and 120 min was 59.5 ± 4.3, 60.8 ± 3.3, 60.0 ± 4.9, 63.4 ± 5.8 and 58.3 
± 1.2, 59.7 ± 1.3, 56.1 ± 1.4, 56.2 ± 1.0 µg/106 cells, respectively.  The ratios of NE/(NE + 
E) release for 30 min in the resting state were 0.30 ± 0.03 (control) and 0.33 ± 0.04 (100 
pg/ml IL-1α), and 0.21 ± 0.02 (5 µM ACh) and 0.21 ± 0.03 (100 pg/ml IL-1α + 5 µM 
ACh), respectively. The ratios in response to 30 µM ACh and 25 mM KCl were also not 
altered by IL-1α. Thus, the content of CA and the ratio of NE and E release were not 
altered by IL-1α, suggesting that IL-1α inhibit the synthesis of neither NE nor E. IL-1β had 
similar effects on CA release (data not shown). 
 
Inhibition of [Ca2+]i rise by IL-1 
 
Stimulated CA release from bovine adrenal chromaffin cells is entirely dependent on the 
presence of extracellular Ca2+. To evaluate the mechanism of IL-1α-induced inhibition of 
CA release, the effect of IL-1α on Ca2+ dynamics was examined. Typical patterns of 
stimulation-induced [Ca2+]i rise and the effects of IL-1α are shown in Fig.1. IL-1α alone 
had little effect on basal [Ca2+]i during the 10 min assay (Fig. 1A-a).  IL-1α reduced the 
peak and the following sustained [Ca2+]i rise induced by excess KCl (Fig. 1A-b).  
To examine the effect of IL-1α on the mobilization of Ca2+ from intracellular Ca2+ stores 
induced by such mechanisms as inositol trisphosphate (IP3)-mediated release and Ca2+-
induced Ca2+ release (CICR), We analyzed the effects of IL-1α on bradykinin- and 
caffeine-induced [Ca2+]i rise in the absence of Ca2+ in the medium. Bradykinin has been 
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shown to increase the production of IP3 and increase Ca2+ mobilization from IP3-sensitive 
stores in chromaffin cells [29]. Caffeine also mobilizes Ca2+ by sensitizing CICR 
mechanisms [22, 30-32]. IL-1α had no effect on either bradykinin- or caffeine-induced 
[Ca2+]i rise in the absence of Ca2+ in the medium (Fig. 1B-a,b).  Effect of IL-1 on Ca2+ 
influx through store-operated Ca2+ channel (SOC) [28] was also examined (Fig. 1B-c). 
Thapsigardin, which is an inhibitor of Ca2+-ATPase, depletes stored Ca2+ without involving 
plasma membrane receptor activation. Thus it is widely used to activate SOC. In 
chromaffin cells in this model, IL-1α had no effect either on thapsigargin-induced [Ca2+]i 
rise in Ca2+ free condition or on the large increase in [Ca2+]i by the addition of Ca2+ into the 
medium after thapsigargin treatment (Fig.1B-c).  
Fig. 2 shows the concentration-dependent effects of IL-1α and IL-1β on stimulation-
evoked [Ca2+]i rise. Both cytokines significantly inhibited [Ca2+]i rise induced by excess 
KCl or ACh at 1 pg/ml with maximal reduction by about 40 % at 10 pg/ml. Increasing 
concentration of IL-1α up to 10 ng/ml induced no further increase in the inhibitory effects 
(Fig. 2). The inhibitory effects of IL-1α, IL-1β on [Ca2+]i rise and on CA release appeared 
after a latent period of several minutes and intensified as a function of incubation time (data 
not shown). 
 
Inhibition of VOCC by IL-1 
 
In agreement with the restoration of the inhibitory effect of IL-1α on CA release in Ca2+-
sucrose medium (Table 1), IL-1α reduced 17 mM KCl-induced [Ca2+]i rise in Ca2+-sucrose 
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medium where the VOCC is the main route for the increase in [Ca2+]i as shown by the 
blockade of 17 mM KCL-induced [Ca2+]i rise by diltazem, an inhibitor of VOCC (Fig. 3). 
Taken together with the disappearance of the inhibitory effect of IL-1α on veratridine-
induced CA release in the presence of diltiazem, these findings suggest that VOCC is 
involved at the site of IL-1α action. 
Adrenal chromaffin cells develop several types of VOCC; P/Q type, N-type and L-type. 
As VOCC was the suggested site of inhibition for IL-1α by the results presented in Table 1 
and Fig. 1, it is important to determine the type of VOCC that the target for IL-1s. This 
issue was addressed using specific VOCC inhibitors. ω-Conotoxin GVIA (N-type channel 
blocker) had little affect on excess KCl-induced [Ca2+]i rise, suggesting that the 
contribution of the N-type channel is small. ω-Conotoxin GVIA had little affect on the 
inhibitory effect of IL-1α. ω-Agatoxin IVA (P/Q-type channel blocker) reduced both the 
peak rise and sustained [Ca2+]i rise, suggesting that the P/Q-type channel significantly 
contributes to the rise of [Ca2+]i. In the presence of ω-agatoxin IVA, the inhibitory effect of 
IL-1α was abolished. ω-Conotoxin MVIIC (N/P/Q-type blocker) also reduced the excess 
KCl-induced [Ca2+]i rise and abolished the inhibitory effect of IL-1α. Nicardipine (L-type 
channel blocker) significantly reduced the excess KCl-induced peak [Ca2+]i rise and  
attenuated the sustained rise close to the basal level, suggesting that the L-type channel 
plays a major role in the excess KCl-induced [Ca2+]i rise. In the presence of nicardipine 
with or without of ω-conotoxin GVIA, the [Ca2+]i rise induced by excess KCl was further 
reduced by IL-1α. In the presence of nicardipine and ω-agatoxin IVA, [Ca2+]i rise was 
minimal and was not affected by IL-1α (Fig. 3). Therefore, the remaining [Ca2+]i rise in the 
 12
presence of nicardipine and ω-conotoxin GVIA could be due to the P/Q-type channel and 
IL-1α inhibits this channel. Thus, the blockers of the P/Q type channel, ω-agatoxin IVA or 
ω-conotoxin MVIIC, presented alone or in any combination with other blockers prevented 
the inhibitory effect of IL-1α on excess KCl-induced [Ca2+]i rise. Similar results were 
obtained using IL-1β (Fig. 3), and ACh as a stimulant (data not shown). These results 
clearly demonstrated that IL-1 inhibited specifically the P/Q type Ca2+ channel.  
In agreement with the effects of these VOCC inhibitors on  [Ca2+]i rise, CA release 
evoked by excess KCl was significantly reduced by ω-agatoxin IVA and ω-conotoxin 
MVIIC, and more profoundly by nicardipine and nifedipine, but not by ω-conotoxin GVIA 
(Table 2). The basal values of CA release in the presence of drugs tested were 0.08 ± 0.01; 
ω-agatoxin IVA, 0.09 ± 0.01; ω-conotoxin GVIA, 0.09 ± 0.01; ω-conotoxin MVIIC, 0.10 ± 
0.01; ω-agatoxin IVA + ω-conotoxin GVIA, 0.09 ± 0.01; nicardipine, 0.09 ± 0.01; 
nifedipine, 0.1 ± 0.01 μg/106 cells, respectively. The inhibitory effect of IL-1α on CA 
release was also abolished in the presence of the blockers of the P/Q type channel (ω-
agatoxin IVA and ω-conotoxin MVIIC) (Table 2). IL-1α still produced the inhibitory effect 
on excess KCl-evoked CA release even in the presence of nicardipine or nifedipine until 
CA release was profoundly blocked by these inhibitors. Basal CA release in the presence of 
the drugs tested was not altered by IL-1α 
 
3.3. Effects of inhibitors of signaling on IL-1-induced inhibition of [Ca2+]i rise  
Although the intracellular signal transduction systems coupled to IL-1 receptors are still 
uncertain, Plata-Salamán and ffrench-Mullen [33] reported that the depression of Ca2+ 
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channel current in hippocampal neurons by IL-1β was prevented by inhibitors of protein 
kinase C and suggested the involvement of protein kinase C. In the present study, the 
inhibitors for protein kinase C, staurosporine and A kinase, H-89 had no influence on IL-
1α-induced inhibition of secretory response (data not shown). In cells pretreated with an 
inhibitor of tyrosine kinase, herbimycin A, IL-1α lost its inhibitory effect on excess KCl-
evoked [Ca2+]i rise. Involvement of mitogen-activated protein kinases (MAP kinases) in the 
production of the inhibitory effect of IL-1 on excess KCl-evoked [Ca2+]i rise were 
examined using the inhibitors. MEK/ERK inhibitors, U0126 and PD 98059 significantly 
attenuated the effect of IL-1. U0126 and PD 98059 increased basal [Ca2+]i. p38 inhibitor, 
SB 202190 and JNK inhibitor, SP600125 did not affect on the effect of IL-1. An inhibitor 
of Gi/Go protein coupled pathway, pertussis toxin (PTX) had no effect on the inhibitory 
effect of IL-1(Table 3). 
  
Discussion 
 
     Intraventricular injections of cytokines transiently increase blood CA [34]. Yanagihara 
et al. [18] reported that when bovine adrenal chomaffin cells were cultured with IL-1 for 24 
hrs, a small amount of CA was released into the medium. Another study reported that IL-1 
and IL-2 did not stimulate epinephrine release from porcine chromaffin cells [35]. The 
present study demonstrated noteworthy inhibitory effects of IL-1α and IL-1β on [Ca2+]i rise 
and CA release in cultured bovine chromaffin cells. The effects were blocked by the 
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endogenous IL-1 receptor inhibitory protein, IL-1RA. Thus, IL-1s may interact with the 
type 1 IL-1 receptor expressed in the chromaffin cells to produce the inhibitory effects. 
The mechanism of IL-1-induced inhibition of CA release does not seem related to 
inhibition of CA biosynthesis because the total CA content and the ratio of NE/(NE + E) 
were not altered by IL-1. [Ca2+]i rise is essential for stimulation-secretion coupling in 
adrenal chromaffin cells. The IL-1-induced inhibition of [Ca2+]i rise evoked by excess KCl 
and ACh could be a reliable cause of the IL-1 inhibition of the stimulation-evoked 
secretion. The sources of Ca2+ for the [Ca2+]i rise in response to physiological stimulation 
in adrenal chromaffin cells are the influx of Ca2+ through plasma membrane via VOCC, 
nicotinic ACh receptor and SOC, and the mobilization of Ca2+ from intracellular Ca2+ 
stores induced by such mechanisms as IP3-mediated release and CICR. Since IL-1 
decreased the [Ca2+]i rise evoked not only by ACh but also by excess KCl depolarization, it 
is unlikely that the inhibitory effects of IL-1 are due to modification of nicotinic ACh 
receptor functions. The evidence that the inhibitory effect of IL-1α on veratridine-induced 
CA release was lost in the presence of the VOCC blocker, diltiazem, suggests that IL-1 
blocks VOCC. This idea is reinforced by the observation that IL-1α decreased the KCl-
induced [Ca2+]i rise even in a Ca2+-sucrose medium,  which rules out any involvement of an 
effect on the Na+ channel. Moreover, there is some evidence that IL-1 suppresses ion 
channel activities. For examples, IL-1β depresses the voltage-activated inward current of 
the identified central neurons of Helix pomatia [36], the voltage-gated Ca2+ channel 
currents in guinea-pig hippocampal CA1 neurons [33], L- and N-type Ca2+ channel activity 
in rat cortical neurons [37] and L-type Ca2+ current activated by adrenergic receptor 
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stimulation in rat ventricular myocytes [38]. Based on the effect of IL-1 on bradykinin- and 
caffeine-induced [Ca2+]i  rise and on thapsigargine-induced Ca2+ entry, it does not seem 
that [Ca2+]i  rise mediated by IP3, CICR and SOC is involved in the IL-1-induced inhibition 
of [Ca2+]i  rise. In addition, IL-1 had no effect on exocytosis triggered by Ca2+, evaluated 
by CA release induced by the direct increase in Ca2+ concentration in medium in digitonin-
permeabilized cells. Therefore, we conclude that VOCC is a critical site for IL-1 action in 
decreasing [Ca2+]i rise, resulting in the inhibition of CA release. 
To identify which type of Ca2+ channels are involved in the inhibitory effect of IL-1 on 
[Ca2+]i,  the effects of specific blokers for L-, N- and P/O-type channels on the effect of IL-
1α were examined. The inhibitory effect of IL-1α was abolished in the presence of only the 
blockers of the P/Q-type channel (ω-agatoxin IVA or ω-conotoxin MVIIC) suggesting that 
IL-1α specifically inhibits the P/Q-type Ca2+ channel. It has been demonstrated that Q-type 
Ca2+ channels are coupled more tightly to active exocytotic sites than L-type channels [39]. 
Actually, inhibitors for P/Q-type, but not N-type VOCC, reduced CA release induced by 
excess KCl, although the secretory response in adrenal chromaffin cells is predominantly 
dependent on L-type VOCC. Therefore, the inhibition of P/Q-type VOCC by IL-1s can be 
reflected in the reduction of CA release. It is interesting to consider the physiological 
regulation by IL-1 on CA release in human adrenal chromaffin cells where P/Q-type Ca2+ 
channels are primarily expressed [40]. Also, P/Q-type channels are developed in brain and 
motor nerve endings. Several diseases, such as episodic ataxia type2; EA2, familial 
hemiplegic migraine [41] and spinocerebellar ataxia type 6; SCA6 [42] and Lambert-Eaton 
Myasthenia syndrome (LEMS) [43], are due to disfunction of P/Q-type channels in the 
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brain. Whether or not IL-1 modifies P/Q-type Ca2+ channels in nervous systems as a 
physiological and/or pathological state remains to be elucidated but is a matter of keen 
interest.  
One persistent aspect of IL-1 signal transduction is the activation of MAP-kinases, which 
are very rapid cellular responses, and it represents a point of convergence in intracellular 
signaling activated by tyrosine kinases, by protein kinase C and A kinase [44]. Although 
the importance of MAP kinase pathway in the regulation of gene expression is well 
appreciated, it contributes to other forms of short-term, post-translational modulation. A 
recent study showed that IL-1β enhanced NMDA receptor function through activation of 
Src tyrosine kinases and subsequent phosphorylation of NMDA receptor subunit NR2A/B 
[45]. The present observations that a tyrosine kinase inhibitor, herbimycin, MEK/ERK 
inhibitors, U0126 and PD 98059, but not p38 inhibitor, SB 202190, JNK inhibitor, 
SP600125 and Gi/Go protein inhibitor, PTX, inhibited the induction of the inhibitory action 
of IL-1 suggest that IL-1 may regulate P/Q type VOCC through a tyrosine kinase-, 
MEK/ERK-mediated pathway. MEK/ERK inhibitors by themselves increased basal [Ca2+]i, 
suggesting that this signaling pathway negatively regulate P/Q type VOCC. Taken together, 
IL-1 may activate MEK/ERK pathway to facilitate negative regulation of P/Q type 
channels. Actually we observed previously that IL-1α increases p42/44 MAP kinase in 
chromaffin cells (unpublished observation) and thus a possibility may arise that P/Q 
channel activity is regulated by phosphorylation of the channel by MAP kinases. Whether 
the inhibitory effect of IL-1 is mediated through the direct phosphrylation of P/Q channel 
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and/or associated proteins or the synthesis of proteins that interact with the channel remains 
for further study.   
The presence and release of IL-1 in adrenal chromaffin cells have been demonstrated 
[12-16]. Thus, it is possible that IL-1 released from chromaffin cells produces a feedback 
inhibition of CA release from the cells. Currie et al. [46] reported that resident 
macrophages in the adrenal gland release unidentified messengers that inhibit ICa in the 
chromaffin cell, suggesting paracrine signaling between macrophage and chormaffin cell 
Ca2+ channels. The blood level of IL-1 increases under such circumstances as infection or 
severe trauma to something on the order of pg/ml, though circulating IL-1 is normally very 
low [4-9]. In acute toxicity caused by clinically administered cytokines for the treatment of 
cancer or chronic infections, IL-1 causes significant, long lasting hypotension [47-49]. The 
evidence demonstrated from the present study may provide the possibility that IL-1 plays a 
signaling role in these physiological and pathological conditions. 
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Figure Legends  
Fig.1. Effects of IL-1α on stimulation-induced rise of [Ca2+]i in cultured bovine adrenal 
chromaffin cells. Following 30 min pretreatment with or without 100 pg/ml IL-1α in the 
dark at 32 °C, cells were washed rapidly with fresh medium to remove extracellular 
(leaked) dye before the fluorescence measurement. They were then incubated for 3 min 
followed by the indicated stimulants (A, B). The cells were exposed to Ca2+-deficient 
medium (containing 0.1 mM EGTA), B-a,b,c for 3 min before challenge with the indicated 
stimulants. CaCl2 (1.3 mM) were added 9 min after extracellular Ca2+ deprivation (B-c). 
The results of a typical experiment are shown (gray traces are in the absence of IL-1α, (A-
a, B)). The arrows on the traces indicate the addition of appropriate stimulants. 
Experiments were repeated with at least three different batches of cells with similar results. 
 
Fig. 2. Inhibitory effects of IL-1α and IL-1β on [Ca2+]i rise  induced by excess KCl or ACh 
in bovine adrenal chromaffin cells. Concentration-response curve for the effects of IL-1α 
and IL-1β on stimulation-induced rise of [Ca2+]i. Experimental design was similar to those 
described in Fig. 1. Values are the mean ± SEM of the peak rise of [Ca2+]i (n= 4 to 20). 
Significantly different from the corresponding control at * p<0.05, ** p<0.01.  
 
Fig. 3. Effects of various voltage sensitive Ca2+ channel inhibitors on IL-1 inhibition of 
stimulation-evoked [Ca2+]i rise in cultured bovine adrenal chromaffin cells. Following 30 
min pretreatment with or without 100 pg/ml IL-1α and IL-1β, cells were exposed to Ca2+-
sucrose medium or normal medium with or without various voltage sensitive Ca2+ channel 
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inhibitors for 3 min before challenge with 17 mM KCl. The results of a typical experiment 
are shown (gray traces are in the absence of IL-1). The arrows on the traces indicate the 
addition of 17 mM KCl. Experiments were repeated with at least three different batches of 
cells with similar results. ω-AgTx IVA, ω-agatoxin IVA; ω-CgTx GVIA, ω-conotoxin 
GVIA; ω-CgTx MVIIC, ω-conotoxin MVIIC 
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Table 1. Iinhibition of stimulation-evoked CA release induced by IL-1α from cultured 
bovine adrenal chromaffin cells 
   Increase in CA release (μg/106 cells)
 
Stimulants 
 
Preincubation 
– IL1α + IL-1α 
(100 pg/ml) 
Exp.1  Intact cells    
ACh               3 μM  0.36 ± 0.09 0.22 ± 0.08* 
5 μM  1.16 ± 0.13 0.68 ± 0.09* 
10 μM  1.98 ± 0.15 1.32 ± 0.10* 
30 μM  2.80 ± 0.14 1.74 ± 0.10* 
100 μM  2.64 ± 0.17 1.79 ± 0.12* 
    
KCl             20 mM  0.42 ± 0.02 0.22 ± 0.04* 
25 mM  0.90 ± 0.08 0.56 ± 0.07* 
50 mM  1.59 ± 0.07 1.15 ±0.05* 
75 mM  1.61 ± 0.10 1.16 ± 0.08* 
    
KCl             25 mM Vehicle 0.99 ± 0.08 0.67 ± 0.05* 
 Ca2+-Sucrose solution 1.23 ± 0.12 0.81 ± 0.06* 
    
Veratridine  25 μM Vehicle 0.74 ± 0.08 0.56 ± 0.04* 
 Diltiazem     30 μM 0.45 ± 0.06 0.47 ± 0.08 
    
Exp.2  Digitonin-permeabilized cells   
Free Ca2+ concentration   
100 nM  0.73 ± 0.08 0.77 ± 0.08 
     
Exp.3  Intact cells     
Stimulant Preincubation 1 Preincubation 2   
ACh               5 μM Vehicle Vehiclea 1.30 ± 0.04 0.84 ± 0.05* 
5 μM Vehicle IL-1RA 100 ng/mlb 1.28 ± 0.06 1.26 ± 0.07 
5 μM IL-1α 100 pg/ml Vehiclec 0.83 ± 0.05 0.85 ± 0.04 
5 μM IL-1α 100 pg/ml IL-1RA 100 ng/mld 0.84 ± 0.05 0.84 ± 0.02 
 
Exp. 1. Cultured bovine adrenal chromaffin cells were incubated for 30 min with or without 100 
pg/ml IL-1α. The medium was replaced with fresh medium containing corresponding IL-1α and 
ACh, excess KCl at the concentrations indicated, then further incubated for 9 min at 37 °C.  
Diltiazem was added 3 min before challenge with veratridine. 
Exp. 2. Following 30 min preteatment with or without 100 pg/ml IL-1α, cells were permeabilized 
for 5 min with 10 μM digitonin in Ca2+-free KGP medium. Extracellular fluids were replaced with 
fresh medium containing the indicated concentration of free Ca2+. 
Exp. 3. Cells were preincubated, (a) without IL-1α (preinc. 1) and without IL-1RA (preinc. 2), (b) 
without IL-1α (preinc. 1) and with IL-1RA (preinc. 2), (c) with IL-1α (preinc. 1) and without IL-
1RA (preinc. 2),  (d) with IL-1α (preinc. 1) and with IL-1RA (preinc. 2). Preincubation 1 and 2 
were performed for 30 and 60 min, respectively. After the preincubation 2, all cells were challenged 
with ACh as in Exp. 1. Basal release in intact cells with normal solution or Ca2+-Sucrose solution 
and permeabilized cells (at 10 nM free Ca2+ concentration) were 0.08 ± 0.01, 0.55 ± 0.02 and 0.17 ± 
0.02 μg/106 cells, respectively. The basal CA release were not altered by the presence of drugs 
tested and/or IL-1α 
Values are the mean ± SEM of the net increase in CA release attained with four samples in a batch.  
Significantly different from the corresponding control at * p<0.01. 
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Table 2. Effects of various types of voltage-operated Ca2+ channel antagonists on IL-1α 
induced inhibition of excess KCl-evoked CA release from cultured bovine adrenal 
chromaffin cells.  
 KCl (25 mM)-induced CA release  
(μg/106 cells) 
Addition – IL1α  (100 pg/ml) + IL1α  (100 pg/ml) 
None 0.74 ± 0.08 0.49 ± 0.04* 
ω-AgTx IVA                 0.3 μM 0.44 ± 0.06 0.40 ± 0.05 
ω-CgTx GVIA                 1 μM 0.68 ± 0.07 0.45 ± 0.04* 
ω-CgTx MVIIC               1 μM 0.42 ± 0.06 0.39 ± 0.03 
ω-AgTx IVA + ω-CgTx GVIA 0.38 ± 0.05 0.37 ± 0.05 
   
None 0.94 ± 0.04 0.70 ± 0.03* 
Nicardipine                      3 nM 0.75 ± 0.01 0.63 ± 0.02* 
30 nM 0.44 ± 0.01 0.39 ± 0.01* 
300 nM 0.18 ± 0.02 0.15 ± 0.01 
   
None 0.93 ± 0.02 0.75 ± 0.01* 
Nifedipine                      10 nM 0.70 ± 0.03 0.56 ± 0.02* 
100 nM 0.35 ± 0.01 0.27 ± 0.01* 
1 μM 0.18 ± 0.01 0.12 ± 0.01 
3 μM 0.12 ± 0.01 0.09 ± 0.01 
 
Experimental design was similar to those described in table 1.  Ca2+ channel antagonists 
were pretreated for 3 min before challenge with KCl. Values are the mean ± SEM of the net 
increase in CA release attained with four samples in a batch.  The basal CA release in the 
presence of drugs tested (basal values were 0.08 ± 0.01;ω-AgTx IVA, 0.09 ± 0.01; ω-CgTx 
GVIA, 0.09 ± 0.01; ω-CgTx MVIIC, 0.10 ± 0.01; ω-AgTx IVA + ω-CgTx GVIA, 0.09 ± 
0.01; nicardipine, 0.09 ± 0.01; nifedipine, 0.1 ± 0.01 μg/106 cells, respectively). ). The 
basal CA release in the presence of drugs tested were not altered by IL-1α Significantly 
different from the corresponding control at * p<0.01. ω-AgTx IVA, ω-agatoxin IVA; ω-
CgTx GVIA, ω-conotoxin GVIA; ω-CgTx MVIIC, ω-conotoxin MVIIC 
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Table 3. Effects of tyrosine kinase inhibitor, specific inhibitors of MEK/ERK, p38 or Jun 
kinase pathway and pertussis toxin (PTX) on IL-1α induced inhibition of excess KCl-
evoked [Ca2+]i rise in cultured bovine adrenal chromaffin cells 
  [Ca2+]i rise (nM) 
 
Stimulants 
 
Preincubation 
− IL-1α + IL-1α 
(100 pg/ml) 
Ratio 
(+IL-1α/ −IL-1α) 
KCl   17 mM Vehicle 212.3 ± 7.9 135.2 ± 6.1** 0.636 ± 0.014 
 Herbimycin A    1 μM 237.7 ± 1.0 220.0 ± 3.5 0.925 ± 0.017## 
     
KCl   17 mM Vehicle 231.2 ± 6.9 157.2 ± 5.8** 0.678 ± 0.012 
 PD 98059        30 μM 347.8 ± 33.1 308.9 ± 12.7 0.898 ± 0.035## 
 60 μM 464.9 ± 38.3 401.1 ± 31.4* 0.870 ± 0.041# 
 U0126              10 μM 303.2 ± 11.2 277.8 ± 17.5* 0.898 ± 0.020## 
 25 μM 419.9 ± 16.2 398.1 ± 16.7 0.959 ± 0.021## 
 SB202190          1 μM 258.3 ± 2.7 169.5 ± 3.3** 0.658 ± 0.011 
 10 μM 202.1 ± 13.7 154.9 ± 7.6** 0.682 ± 0.028 
 SP 600125          1 μM 217.9 ± 13.3 162.9 ± 9.4** 0.710 ± 0.025 
 10 μM 206.9 ± 14.9 163.4 ± 9.6** 0.755 ± 0.029 
     
KCl   17 mM Vehicle 220.9 ± 6.3 150.3 ± 5.8** 0.686 ± 0.026 
 PTX              20 ng/ml 207.6 ± 3.9 142.5 ± 2.6** 0.690 ± 0.017 
Experimental design was similar to those described in table 1 and Fig. 1. Herbimycin A, 
was added 90 min before the addition of IL-1α. PD 98059, U0126, SB 202190, and SP 
600125 were added 30 min before the addition of IL-1α. Pertussis toxin (PTX) was added 
12 hr before the addition of IL-1α. Values are the mean ± SEM of the peak rise of [Ca2+]i 
(n=5 to 9). The basal [Ca2+]i in the presence of drugs tested (basal values were 87.6 ± 1.5; 
herbimycin A, 89.9 ± 6.1; PD 98059, 109.9 ± 9.4; U0126, 86.4 ± 2.7; SB202190, 82.5 ± 
4.6; SP 600125, 108.5 ± 2.8; PTX, 109.5 ± 2.3  nM, respectively).The basal [Ca2+]i in the 
presence of drugs tested were not altered by IL-1α. Significantly different from the 
corresponding control (−IL-1α) at * p<0.05, ** p<0.01; Significantly different from the 
corresponding control ratio (+IL-1α/ −IL-1α) at #p<0.05, ##p<0.001. 
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